Abstract
Our goal was determine the effects of dydrogesterone supplementation to reduce the incidence of preeclampsia (PE) in early pregnancy (from 6 to 20 weeks of gestation). A total of 406 pregnant women were involved into the study. The Study group enrolled 169 women, supplemented with dydrogesterone at a dose of 30 mg/d 6–20 weeks of gestation compared with the control group (237 subjects) – without dydrogesterone supplementation. The women were randomized by age, race, obstetrics complications, and their somatic history. The use of dydrogesterone in early pregnancy – before 20 weeks of gestation (at a dose of 30 mg/d) with high-risk factors of PE contributed to a statistically significant reduction in the frequency of this complication (13.1% and 71.4%, p < .001). It was seen, that women who took dydrogesterone developed significantly less such disorders like hypertension (3.2% and 71.2%, p < .001), proteinuria (0.0% and 66.18%, p < .001), fetal growth retardation syndrome (2.2% and 21.58%, p < .001), destroy of uteri-placenta velocity (3.2% and 21.58%, p < .001), preterm labor (8.6% and 53.95%, p < .001). Dydrogesterone supplementation in the first and second period of pregnancy (from 6 to 20 weeks of gestation) significantly reduced the incidence of PE in women with higher risk pregnancy.
摘要
我们的目标是明确补充地屈孕酮对降低妊娠早期(妊娠6至20周)先兆子痫(PE)发病率的影响。共有406名孕妇参与了这项研究, 研究组招募了169名妇女, 与没有补充地屈孕酮的对照组(237名受试者)相比, 研究组在妊娠6-20周时以30 mg/d的剂量补充地屈孕酮。这些妇女按年龄, 种族, 产科并发症和躯体病史随机分组, 有PE高危因素的孕妇在妊娠早期-妊娠20周前使用地屈孕酮(剂量为30 mg/d)统计学上显着降低这种并发症的发生率(13.1%和71.4%, p<.001)。结果显示, 服用地屈孕酮的孕妇患高血压(3.2%和71.2%, p<.001), 蛋白尿(0.0%和66.18%, p<.001), 胎儿发育迟缓综合征(2.2%和21.58%, p<.001), 子宫胎盘破坏速度(3.2%和21.58%, p<.001), 早产(8.6%和53.95%, p<.001)等疾病的发生率明显降低。在妊娠的第一和第二阶段(妊娠6至20周)补充地屈孕酮显著降低了妊娠高危妇女的PE发病率。
The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.
Disclosure statement
No potential conflict of interest was reported by the authors.